Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
- Details
- Category: Financial
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the three and twelve months ended December 31, 2007. Onyx reported a net loss of $11.7 million, or $0.21 per share, for the fourth quarter of 2007 compared to a net loss of $20.7 million, or $0.47 per share, in the same period in the prior year.
Bayer and Onyx Provide Update on Phase III Trial of Nexavar®
- Details
- Category: Bayer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced that a Phase III trial evaluating Nexavar® (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the independent Data Monitoring Committee (DMC) concluded that the study would not meet its primary endpoint of improved overall survival.
Trasylol® - One Thousand Lives A Month
- Details
- Category: Product
A renowned researcher estimates that 22,000 patients could have been saved if the Food and Drug Administration removed the heart surgery drug Trasylol two years ago. Scott Pelley reports.
CBSNews.com
CBSNews.com
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline
- Details
- Category: Financial
EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to US$44 million, comprising an upfront fee and development milestones, plus royalties on future sales.
FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim's investigational cancer treatment BIBW 2992 has recently received a Fast Track Designation status by the FDA. Under this designation, Boehringer Ingelheim will conduct a pivotal trial programme studying BIBW 2992 in a non-small cell lung cancer (NSCLC) patient group where prior treatment with reversible EGFR inhibitors has failed.
Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin)
- Details
- Category: Abbott
Abbott received U.S. Food and Drug Administration (FDA) approval for SIMCOR(R), the first fixed-dose combination of two widely prescribed cholesterol therapies, Niaspan(R) (Abbott's proprietary niacin extended-release) and simvastatin. SIMCOR is approved for use along with diet to lower levels of elevated total cholesterol, LDL "bad" cholesterol and triglycerides, and to raise HDL "good" cholesterol in patients with complex lipid disease when treatment with simvastatin or Niaspan monotherapies are not considered adequate.
Pharmion and MethylGene Announce U.S. Orphan Drug Designation
- Details
- Category: Product
Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of acute myelogenous leukemia (AML) in the United States.
More Pharma News ...
- AstraZeneca and Nomura Phase4 Ventures Announce Creation of New Company "Albireo"
- The Medicines Company Reports Full Year and Fourth Quarter 2007 Financial Results
- Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
- First Head to Head Study Comparing CRESTOR and LIPITOR®
- Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
- Cleviprex(TM) Demonstrated Rapid, Precise Blood Pressure Control in High-Risk Patients
- Record operating results for Roche again in 2007